Drug intelligence / Profile preview

Double anti-B837-ADC

Development stage: Preclinical
Lead developer: Nanolattix
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Double anti-B837-ADC is a preclinical bispecific antibody-drug conjugate (ADC) being developed by Nanolattix. The agent utilizes a bispecific antibody backbone to target specific antigens associated with solid tumors, specifically colorectal cancer, lung cancer, and breast cancer. By combining the dual-targeting capability of a bispecific antibody with a cytotoxic payload, the drug is designed to enhance tumor selectivity and therapeutic efficacy compared to traditional monoclonal ADCs. As of the latest pipeline updates, the candidate is undergoing preclinical evaluation to support future clinical development.

Beyond the preview

Go deeper on Double anti-B837-ADC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Double anti-B837-ADC.

Explore the full profile